drugset / Trial / NCT05576584
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets
Phase 1
Unknown
114 enrolled
Fujian Akeylink Biotechnology Co., Ltd.
The First Hospital of Jilin University · collab
RandomizedSequentialQuadruple-blindOther
Summary
This phase I clinical study is a phase I clinical study on the safety, tolerability, pharmacokinetic characteristics and food effects of single / continuous administration in Chinese adult healthy subjects
Timeline
- Start
- 2022-07-19
- Primary completion
- 2023-12-28
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GST-HG121 | Unknown | 5 mg | Oral |
| Comparator | GST-HG121 | Unknown | 15 mg | Oral |
| Comparator | GST-HG121 | Unknown | 30 mg | Oral |
| Comparator | GST-HG121 | Unknown | 60 mg | Oral |
| Comparator | GST-HG121 | Unknown | 100 mg | Oral |
| Comparator | GST-HG121 | Unknown | 150 mg | Oral |
| Comparator | GST-HG121 | Unknown | 200 mg | Oral |
Indications
No indication recorded.